Mast Therapeutics is an advanced clinical stage biopharmaceutical company focusing on the development of MST-188 as a potential treatment resolving vaso-occlusive crisis (VOC) in sickle cell disease (SCD) patients. The company is conducting a Phase III pivotal (EPIC) study and potentially to report top-line results in late 2015. Should the study outcome be positive and potentially received approval, MST-188 could potentially be the first VOC in SCD therapeutic launch in the U.S. (possibly in 2017). MST-188 is also in clinical studies (both ongoing and in planning) in other cardiovascular indications, such as acute limb ischemia (ALI) and heart failure. The company’s second asset, AIR001 has the potential as a treatment in pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction (HFpEF).